Vaxcyte, Inc. (PCVX) NASDAQ
54.72
+0.74(+1.37%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
54.72
+0.74(+1.37%)
Currency In USD
| Previous Close | 53.98 |
| Open | 53.94 |
| Day High | 56.23 |
| Day Low | 53.17 |
| 52-Week High | 75.33 |
| 52-Week Low | 27.66 |
| Volume | 3.91M |
| Average Volume | 1.36M |
| Market Cap | 7.88B |
| PE | -9.72 |
| EPS | -5.63 |
| Moving Average 50 Days | 54.82 |
| Moving Average 200 Days | 42.62 |
| Change | 0.74 |
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech